sparsentan (FILSPARI) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
  • InChIKey: WRFHGDPIDHPWIQ-UHFFFAOYSA-N
  • Mol. Mass: 592.76
  • ALogP: 6.54
  • ChEMBL Molecule:
    sparsentan  
More Chemistry

Pharmacology

Alternative names

ps433540 | ps-433540 | re-021 | sparsentan

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (1)


 

Glomerulonephritis, IGA (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 2)

Autoimmune Diseases (Phase 2)

Cardiovascular Diseases (Phase 2)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 3)

Healthy Volunteers (Phase 1)

Hypertension (Phase 2)

IgA Vasculitis (Phase 2)

Immune System Diseases (Phase 2)

Kidney Diseases (Phase 2)

Nephritis, Hereditary (Phase 2)

Nephrosis, Lipoid (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue